Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ATYPICAL ANTIPSYCHOTIC-DRUGS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 227 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Bubser, M; Backstrom, JR; Sanders-Bush, E; Roth, BL; Deutch, AY
      Distribution of serotonin 5-HT2A receptors in afferents of the rat striatum

      SYNAPSE
    2. Rodriguez, JJ; Garcia, DR; Nakabeppu, Y; Pickel, VM
      FosB in rat striatum: Normal regional distribution and enhanced expressionafter 6-month haloperidol administration

      SYNAPSE
    3. Koskinen, T; Sirvio, J
      Studies on the involvement of the dopaminergic system in the 5-HT2 agonist(DOI)-induced premature responding in a five-choice serial reaction time task

      BRAIN RESEARCH BULLETIN
    4. Stutzmann, GE; Marek, GJ; Aghajanian, GK
      Adenosine preferentially suppresses serotonin(2a) receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex

      NEUROSCIENCE
    5. Wadenberg, MLG; Browning, JL; Young, KA; Hicks, PB
      Antagonism at 5-HT2A receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    6. Wood, MD; Reavill, C; Trail, B; Wilson, A; Stean, T; Kennett, GA; Lightowler, S; Blackburn, TP; Thomas, D; Gager, TL; Riley, G; Holland, V; Bromidge, SM; Forbes, IT; Middlemiss, DN
      SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

      NEUROPHARMACOLOGY
    7. Marcus, MM; Mathe, JM; Nomikos, GG; Svensson, TH
      Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens

      NEUROPHARMACOLOGY
    8. Aloyo, VJ; Dave, KD; Rahman, T; Harvey, JA
      Selective and divergent regulation of cortical 5-HT2A receptors in rabbit

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    9. Brun, P; Leonetti, M; Sotty, F; Steinberg, R; Soubrie, P; Renaud, B; Suaud-Chagny, MF
      Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist

      JOURNAL OF NEUROCHEMISTRY
    10. Anji, A; Hanley, NRS; Kumari, M; Hensler, JG
      The role of protein kinase C in the regulation of serotonin-2A receptor expression

      JOURNAL OF NEUROCHEMISTRY
    11. Ichikawa, J; Ishii, H; Bonaccorso, S; Fowler, WL; O'Laughlin, IA; Meltzer, HY
      5-HT2A and D-2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-inducedcortical dopamine release

      JOURNAL OF NEUROCHEMISTRY
    12. Rowley, M; Bristow, LJ; Hutson, PH
      Current and novel approaches to the drug treatment of schizophrenia

      JOURNAL OF MEDICINAL CHEMISTRY
    13. Rodriguez, JJ; Garcia, DR; Nakabeppu, Y; Pickel, VM
      Enhancement of laminar FosB expression in frontal cortex of rats receivinglong chronic clozapine administration

      EXPERIMENTAL NEUROLOGY
    14. Naidu, PS; Kulkarni, SK
      Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists

      EUROPEAN JOURNAL OF PHARMACOLOGY
    15. Ichikawa, J; Dai, J; Meltzer, HY
      DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release

      BRAIN RESEARCH
    16. Pehek, EA; McFarlane, HG; Maguschak, K; Price, B; Pluto, CP
      M100,907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex

      BRAIN RESEARCH
    17. Perry, KW; Nisenbaum, LK; George, CA; Shannon, HE; Felder, CC; Bymaster, FP
      The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

      BIOLOGICAL PSYCHIATRY
    18. Sumiyoshi, T; Matsui, M; Yamashita, I; Nohara, S; Kurachi, M; Uehara, T; Sumiyoshi, S; Sumiyoshi, C; Meltzer, HY
      The effect of tandospirone, a serotonin(1A) agonist, on memory function inschizophrenia

      BIOLOGICAL PSYCHIATRY
    19. Di Matteo, V; De Blasi, A; Di Giulio, C; Esposito, E
      Role of 5 HT2C receptors in the control of central dopamine function

      TRENDS IN PHARMACOLOGICAL SCIENCES
    20. Hietala, J; Kuoppamaki, M; Majasuo, H; Palvimaki, EP; Laakso, A; Syvalahti, E
      Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist butnot antagonist binding to 5-HT2c receptors after chronic treatment

      PSYCHOPHARMACOLOGY
    21. Hale, A; Azorin, JM; Kasper, S; Maier, W; Syvalahti, E; Van der Burght, M; Sloth-Nielsen, M; Wehnert, A
      Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    22. Ruiu, S; Marchese, G; Saba, PL; Gessa, GL; Pani, L
      The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex

      MOLECULAR PSYCHIATRY
    23. Procyshyn, RM; Kennedy, NB
      Theoretical basis for loxapine augmentation in risperidone partial responders

      CLINICAL DRUG INVESTIGATION
    24. Edgell, ET; Andersen, SW; Johnstone, BM; Dulisse, B; Revicki, D; Breier, A
      Olanzapine versus risperidone - A prospective comparison of clinical and economic outcomes in schizophrenia

      PHARMACOECONOMICS
    25. Lieberman, JA; Golden, R; Stroup, S; McEvoy, J
      Drugs of the psychopharmacological revolution in clinical psychiatry

      PSYCHIATRIC SERVICES
    26. Spielewoy, C; Roubert, C; Hamon, M; Nosten-Bertrand, M; Betancur, C; Giros, B
      Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice

      BEHAVIOURAL PHARMACOLOGY
    27. Murphy, CA; Feldon, J
      Low-dose clozapine pretreatment partially prevents haloperidol-induced deficits in conditioned active avoidance

      BEHAVIOURAL PHARMACOLOGY
    28. Barrot, M; Marinelli, M; Abrous, DN; Rouge-Pont, F; Le Moal, M; Piazza, PV
      The dopaminergic hyper-responsiveness of the shell of the nucleus accumbens is hormone-dependent

      EUROPEAN JOURNAL OF NEUROSCIENCE
    29. Verhoeff, NPLG; Meyer, JH; Kecojevic, A; Hussey, D; Lewis, R; Tauscher, J; Zipursky, RB; Kapur, S
      A voxel-by-voxel analysis of [F-18]setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia

      PSYCHIATRY RESEARCH-NEUROIMAGING
    30. Simon, VM; Parra, A; Minarro, J; Arenas, MC; Vinader-Caerols, C; Aguilar, MA
      Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride,raclopride and clozapine reduce locomotor activity in mice

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    31. Fink-Jensen, A
      Novel pharmacological approaches to the treatment of schizophrenia

      DANISH MEDICAL BULLETIN
    32. Ohashi, K; Hamamura, T; Lee, Y; Fujiwara, Y; Suzuki, H; Kuroda, S
      Clozapine- and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by beta-adrenoceptors

      NEUROPSYCHOPHARMACOLOGY
    33. Carboni, E; Rolando, MTP; Silvagni, A; Di Chiara, G
      Increase of dialysate dopamine in the bed nucleus of stria terminalis by clozapine and related neuroleptics

      NEUROPSYCHOPHARMACOLOGY
    34. De la Garza, R; Madras, BK
      [H-3]PNU-101958, a D-4 dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non-human primate brain

      SYNAPSE
    35. Aguilar, MA; Mari-Sanmillan, MI; Morant-Deusa, JJ; Minarro, J
      Different inhibition of conditioned avoidance response by clozapine and DAD-1 and D-2 antagonists in male mice

      BEHAVIORAL NEUROSCIENCE
    36. Rosenberg, PB; Rosse, RB; Schwartz, BL; Deutsch, SI
      Nefazodone in the adjunctive therapy of schizophrenia: An open-label exploratory study

      CLINICAL NEUROPHARMACOLOGY
    37. Tarazi, FI; Zhang, KH; Baldessarini, RJ
      Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain

      NEUROSCIENCE LETTERS
    38. Scruggs, JL; Patel, S; Bubser, M; Deutch, AY
      DOI-induced activation of the cortex: Dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons

      JOURNAL OF NEUROSCIENCE
    39. Tyler-McMahon, BM; Boules, M; Richelson, E
      Neurotensin: peptide for the next millennium

      REGULATORY PEPTIDES
    40. Svensson, TH
      Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs

      BRAIN RESEARCH REVIEWS
    41. Zahm, DS
      An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens

      NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
    42. Dossenbach, MRK; Beuzen, JN; Avnon, M; Belmaker, RH; Elizur, A; Mark, M; Munitz, H; Schneidman, M; Shoshani, D; Kratky, P; Grundy, SL; Tollefson, GD
      The effectiveness of olanzapine in treatment-refractory schizophrenia whenpatients are nonresponsive to or unable to tolerate clozapine

      CLINICAL THERAPEUTICS
    43. Nasu, R; Matsuo, H; Takanaga, H; Ohtani, H; Sawada, Y
      Quantitative prediction of catalepsy induced by amoxapine, cinnarizine andcyclophosphamide in mice

      BIOPHARMACEUTICS & DRUG DISPOSITION
    44. Inoue, T; Izumi, T; Maki, Y; Muraki, I; Koyama, T
      Effect of the dopamine D-1/5 antagonist SCH 23390 on the acquisition of conditioned fear

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    45. Robichaud, AJ; Largent, BL
      Recent advances in selective serotonin receptor modulation

      ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 35
    46. Anji, A; Kumari, M; Hanley, NRS; Bryan, GL; Hensler, JG
      Regulation of 5-HT2A receptor mRNA levels and binding sites in rat frontalcortex by the agonist DOI and the antagonist mianserin

      NEUROPHARMACOLOGY
    47. Moller, HJ
      Current assessment of new/atypical neuroleptics

      NERVENARZT
    48. Gilliland, SL; Alper, RH
      Characterization of dopaminergic compounds at hD(2short), hD(4.2) and hD(4.7) receptors in agonist-stimulated [S-35]GTP gamma S binding assays

      NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    49. Okubo, Y; Suhara, T; Suzuki, K; Kobayashi, K; Inoue, O; Terasaki, O; Someya, Y; Sassa, T; Sudo, Y; Matsushima, E; Iyo, M; Tateno, Y; Toru, M
      Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography

      LIFE SCIENCES
    50. Duncan, GE; Miyamoto, S; Leipzig, JN; Lieberman, JA
      Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    51. Liu, W; Wu, CF; Liu, J; Huang, M; Xiao, K
      Differential effects of acute administration of haloperidol and clozapine on ethanol-induced ascorbic acid release in rat striatum

      EUROPEAN JOURNAL OF PHARMACOLOGY
    52. Rollema, H; Lu, Y; Schmidt, AW; Sprouse, JS; Zorn, SH
      5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

      BIOLOGICAL PSYCHIATRY
    53. Jarskog, LF; Mattioli, MA; Perkins, DO; Lieberman, JA
      First-episode psychosis in a managed care setting: Clinical management andresearch

      AMERICAN JOURNAL OF PSYCHIATRY
    54. Sirota, P; Mosheva, T; Shabtay, H; Giladi, N; Korczyn, AD
      Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia

      AMERICAN JOURNAL OF PSYCHIATRY
    55. Tarazi, FI; Baldessarini, RJ
      Dopamine D-4 receptors: significance for molecular psychiatry at the millennium

      MOLECULAR PSYCHIATRY
    56. Drinkenburg, WHIM; Keith, AB; Sahgal, A; Andrews, JS
      Haloperidol-induced within-session response decrement patterns and catalepsy in rats: behavioural dissociation

      BEHAVIOURAL PHARMACOLOGY
    57. Ichikawa, J; Meltzer, HY
      Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    58. Corbett, R; Zhou, L; Sorensen, SM; Mondadori, C
      Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice

      NEUROPSYCHOPHARMACOLOGY
    59. Hemsley, KM; Crocker, AD
      Raclopride and chlorpromazine, but not clozapine, increase muscle rigidityin the rat: Relationship with D-2 dopamine receptor occupancy

      NEUROPSYCHOPHARMACOLOGY
    60. Daniel, DG; Zimbroff, DL; Potkin, SG; Reeves, KR; Harrigan, EP; Lakshminarayanan, M
      Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial

      NEUROPSYCHOPHARMACOLOGY
    61. ABISAAB WM; BUBSER M; ROTH RH; DEUTCH AY
      5-HT2 RECEPTOR REGULATION OF EXTRACELLULAR GABA LEVELS IN THE PREFRONTAL CORTEX

      Neuropsychopharmacology
    62. Spurney, CF; Baca, SM; Murray, AM; Jaskiw, GE; Kleinman, JE; Hyde, TM
      Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats

      SYNAPSE
    63. De Souza, IEJ; Meredith, GE
      NMDA receptor blockade attenuates the haloperidol induction of Fos proteinin the dorsal but not the ventral striatum

      SYNAPSE
    64. Passik, SD; Cooper, M
      Complicated delirium in a cancer patient successfully treated with olanzapine

      JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
    65. Meltzer, HY; McGurk, SR
      The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

      SCHIZOPHRENIA BULLETIN
    66. Dawkins, K; Lieberman, JA; Lebowitz, BD; Hsiao, JK
      Antipsychotics: Past and future - National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998

      SCHIZOPHRENIA BULLETIN
    67. Willins, DL; Berry, SA; Alsayegh, L; Backstrom, JR; Sanders-Bush, E; Friedman, L; Roth, BL
      Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo

      NEUROSCIENCE
    68. Alonso, R; Voutsinos, B; Fournier, M; Labie, C; Steinberg, R; Souilhac, J; Le Fur, G; Soubrie, P
      Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D-2 function

      NEUROSCIENCE
    69. Carta, AR; Gerfen, CR
      Lack of a role for the D-3 receptor in clozapine induction of c-Fos demonstrated in D-3 dopamine receptor-deficient mice

      NEUROSCIENCE
    70. Kawashima, N; Nakamura, A; Okuyama, S; Chaki, S; Tomisawa, K
      Effects of NRA0045, NRA0160, and NRA0215 on regional Fos-like immunoreactivity in the rat brain

      GENERAL PHARMACOLOGY
    71. Tollefson, GD; Dellva, MA; Mattler, CA; Kane, JM; Wirshing, DA; Kinon, BJ
      Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    72. Duncan, GE; Sheitman, BB; Lieberman, JA
      An integrated view of pathophysiological models of schizophrenia

      BRAIN RESEARCH REVIEWS
    73. Richelson, E
      Receptor pharmacology of neuroleptics: Relation to clinical effects

      JOURNAL OF CLINICAL PSYCHIATRY
    74. Montgomery, AMJ; Grottick, AJ
      Neurotransmitter system interactions revealed by drug-induced changes in motivated behavior

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    75. Bond, GR; Meyer, PS
      The role of medications in the employment of people with schizophrenia

      JOURNAL OF REHABILITATION
    76. Dwivedi, Y; Pandey, GN
      Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide-specific phospholipase C (PI-PLC)activity and on mRNA and protein expression of PKC and PLC isozymes in ratbrain

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    77. Marek, GJ; Aghajanian, GK
      5-HT2A receptor or alpha(1)-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex

      EUROPEAN JOURNAL OF PHARMACOLOGY
    78. Kapur, S; Zipursky, RB; Remington, G
      Clinical and theoretical implications of 5-HT2 and D-2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    79. Breier, AF; Malhotra, AK; Su, TP; Pinals, DA; Elman, I; Adler, CM; Lafargue, T; Clifton, A; Pickar, D
      Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response

      AMERICAN JOURNAL OF PSYCHIATRY
    80. Young, CD; Bubser, M; Meltzer, HY; Deutch, AY
      Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation

      PSYCHOPHARMACOLOGY
    81. Goudie, AJ; Smith, JA; Robertson, A; Cavanagh, C
      Clozapine as a drug of dependence

      PSYCHOPHARMACOLOGY
    82. SUZUKI M; SUN YJ; MURATA M; KURACHI M
      WIDESPREAD EXPRESSION OF FOS PROTEIN-INDUCED BY ACUTE HALOPERIDOL ADMINISTRATION IN THE RAT-BRAIN

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    83. TAKAHASHI Y; KUSUMI I; ISHIKANE T; MATSUBARA S; KOYAMA T
      IN-VIVO OCCUPATION OF DOPAMINE D-1, D-2 AND SEROTONIN (5-HT)(2A) RECEPTORS BY SERTINDOLE IN THE RAT-BRAIN

      Journal of psychiatry & neuroscience
    84. TREMBLAY PO; GERVAIS J; ROUILLARD C
      MODIFICATION OF HALOPERIDOL-INDUCED PATTERN OF C-FOS EXPRESSION BY SEROTONIN AGONISTS

      European journal of neuroscience
    85. LIEGEOIS JF; EYROLLES L; BRUHWYLER J; DELARGE J
      DOPAMINE D-4 RECEPTORS - A NEW OPPORTUNITY FOR RESEARCH ON SCHIZOPHRENIA

      Current medicinal chemistry
    86. RODRIGUEZARIAS M; MINARRO J; AGUILAR MA; PINAZO J; SIMON VM
      EFFECTS OF RISPERIDONE AND SCH-23390 ON ISOLATION-INDUCED AGGRESSION IN MALE-MICE

      European neuropsychopharmacology
    87. YOUNG CD; MELTZER HY; DEUTCH AY
      EFFECTS OF DESMETHYLCLOZAPINE ON FOS PROTEIN EXPRESSION IN THE FOREBRAIN - IN-VIVO BIOLOGICAL-ACTIVITY OF THE CLOZAPINE METABOLITE

      Neuropsychopharmacology
    88. Roth, BL; Berry, SA; Kroeze, WK; Willins, DL; Kristiansen, K
      Serotonin 5-HT2A receptors: Molecular biology and mechanisms of regulation

      CRITICAL REVIEWS IN NEUROBIOLOGY
    89. MINABE Y; WATANABE K; NISHIMURA T; ASHBY CR
      ACUTE AND CHRONIC ADMINISTRATION OF CLOZAPINE PRODUCES GREATER PROCONVULSANT ACTIONS THAN HALOPERIDOL ON FOCAL HIPPOCAMPAL SEIZURES IN FREELY MOVING RATS

      Synapse
    90. Degner, D; Ruther, E
      "Atypical" antipsychotic drugs in the treatment of schizophrenia

      NERVENHEILKUNDE
    91. FRIEDMAN JH; GOLDSTEIN S; JACQUES C
      SUBSTITUTING CLOZAPINE FOR OLANZAPINE IN PSYCHIATRICALLY STABLE PARKINSONS-DISEASE PATIENTS - RESULTS OF AN OPEN-LABEL PILOT-STUDY

      Clinical neuropharmacology
    92. MAREK GJ; AGHAJANIAN GK
      5-HYDROXYTRYPTAMINE-INDUCED EXCITATORY POSTSYNAPTIC CURRENTS IN NEOCORTICAL LAYER-V PYRAMIDAL CELLS - SUPPRESSION BY MU-OPIATE RECEPTOR ACTIVATION

      Neuroscience
    93. Vysokanov, A; Flores-Hernandez, J; Surmeier, DJ
      mRNAs for clozapine-sensitive receptors co-localize in rat prefrontal cortex neurons

      NEUROSCIENCE LETTERS
    94. Salamone, JD; Mayorga, AJ; Trevitt, JT; Cousins, MS; Conlan, A; Nawab, A
      Tremulous jaw movements in rats: A model of Parkinsonian tremor

      PROGRESS IN NEUROBIOLOGY
    95. BRODERICK PA; PIERCEY MF
      CLOZAPINE, HALOPERIDOL, AND THE D-4 ANTAGONIST PNU-101387G - IN-VIVO EFFECTS ON MESOCORTICAL, MESOLIMBIC, AND NIGROSTRIATAL DOPAMINE AND SEROTONIN RELEASE

      Journal of neural transmission
    96. HERTEL P; LINDBLOM N; NOMIKOS GG; SVENSSON TH
      MODULATION OF CENTRAL SEROTONERGIC NEUROTRANSMISSION BY RISPERIDONE -UNDERLYING MECHANISM[S] AND SIGNIFICANCE OF ACTION

      Progress in neuro-psychopharmacology & biological psychiatry
    97. TREMBLAY M; ROUILLARD C; LEVESQUE D
      THE ANTISENSE STRATEGY APPLIED TO THE STUDY OF DOPAMINE D-3 RECEPTOR FUNCTIONS IN RAT FOREBRAIN

      Progress in neuro-psychopharmacology & biological psychiatry
    98. WANG ZR; REBEC GV
      NEUROETHOLOGICAL ASSESSMENT OF AMPHETAMINE-INDUCED BEHAVIORAL, CHANGES AND THEIR REVERSAL BY NEUROLEPTICS - FOCUS ON THE AMYGDALA AND NUCLEUS-ACCUMBENS

      Progress in neuro-psychopharmacology & biological psychiatry
    99. WOOD A
      CLINICAL-EXPERIENCE WITH OLANZAPINE, A NEW ATYPICAL ANTIPSYCHOTIC

      International clinical psychopharmacology
    100. QIAN IHP; KUSUMI I; ULPIAN C; TALLERICO T; NAM D; LIU ISC; SEEMAN MV; SEEMAN P
      A HUMAN SEROTONIN-7 RECEPTOR PSEUDOGENE

      Molecular brain research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/10/20 alle ore 04:49:19